biostudies-literatureUnknown7(6)Uehara Y<h4>Background</h4>We analyzed the FGF/FGFR and co-alteration cancer landscape, hypothesizing that combination therapy might be useful in the presence of co-drivers.<h4>Materials and methods</h4>We describe FGF/FGFR-altered pathways, prognosis, and co-alterations [cBioPortal (N = 7574)] and therapeutic outcomes [University of California San Diego Molecular Tumor Board (MTB) (N = 16)].<h4>Results</h4>Patients whose cancers harbored FGF/FGFR alterations (N = 1074) versus those without them (N = 6500) had shorter overall survival (OS) (median: 23.1 versus 26.4 months, P = 0.038) (cBioPortal). Only 6.1% (65/1074 patients) had no pathogenic co-alterations accompanying FGF/FGFR axis abnormalities. The most frequently co-altered pathways/genes involved: TP53 (70%); cell cycle (58%); PI3K (55%); aESMO open100647https://www.ebi.ac.uk/biostudies/studies/S-EPMC9808461biostudies-literatureTargeting the FGF/FGFR axis and its co-alteration allies.PMC9808461Okamura RLee SSicklick JKKurzrock RIkeda SLim HJKim KHUehara YKato SPersha HEAdashek JJfalseTargeting the FGF/FGFR axis and its co-alteration allies.<h4>Background</h4>We analyzed the FGF/FGFR and co-alteration cancer landscape, hypothesizing that combination therapy might be useful in the presence of co-drivers.<h4>Materials and methods</h4>We describe FGF/FGFR-altered pathways, prognosis, and co-alterations [cBioPortal (N = 7574)] and therapeutic outcomes [University of California San Diego Molecular Tumor Board (MTB) (N = 16)].<h4>Results</h4>Patients whose cancers harbored FGF/FGFR alterations (N = 1074) versus those without them (N = 6500) had shorter overall survival (OS) (median: 23.1 versus 26.4 months, P = 0.038) (cBioPortal). Only 6.1% (65/1074 patients) had no pathogenic co-alterations accompanying FGF/FGFR axis abnormalities. The most frequently co-altered pathways/genes involved: TP53 (70%); cell cycle (58%); PI3K (55%); a2022-01-01T00:00:00Z2022 Dec2026-03-16T08:10:30.452Z2025-04-19T04:47:45.493ZS-EPMC98084613645550610.1016/j.esmoop.2022.100647